Shanghai-Hong Kong Zhongke

Biopharmaceutical preclinical research and development service company

Copyright © AnLing Biomed (Suzhou) Co., Ltd. All Rights Reserved Source:Boooming ICP:粤ICP备2022021434号-2 CNZZ

Management Team

Li Ming

ZSHK Laboratories Limited CEO

See more

Dr. Ming LI, currently the CEO of ZSHK Laboratories Limited, has been engaged in preclinical evaluation of drugs for more than ten years. Before founding ZSHK Laboratories Limited Company, Dr. Ming LI was engaged in drug safety evaluation at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and presided over the construction of China's first GLP laboratory that complies with EU multi-country certification.
Dr. Ming LI received his Ph.D. in Pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. At the same time, he obtained a double master's degree in EMBA from Antai College of Economics and Management of Shanghai Jiao Tong University and KEDGE Business School in France.

Jin Yi

ZSHK Laboratories Limited COO
General Manager of Anling Biomedical (Shenzhen) Co., Ltd.

See more

Jin Yi is currently the COO of ZSHK Laboratories Limited Group and the general manager of Anling Biopharmaceutical (Shenzhen) Co., Ltd. He has nearly 20 years of international and domestic drug GLP experience. Before the establishment of ZSHK Laboratories Limited Group, he has been engaged in drug safety evaluation in Shanghai Institute of Materia Medica, Chinese Academy of Sciences for a long time, and served as director of quality assurance department and deputy director of safety evaluation center. After many certification inspections and on-site inspections of Belgium and Sweden OECD GLP, UK MHRA GLP, US FDA GLP, China NMPA GLP, and South Korea KFDA remote GLP inspection. The GLP laboratory under construction and operation supports a number of domestic and foreign pharmaceutical companies to conduct clinical research on R&D drugs in North America, the United Kingdom, Germany, Sweden, South Korea, and Australia.

Other current social positions: Chairman of the Quality Assurance Committee of the Chinese Society of Toxicology (CSQA), Executive Director of the Seventh Council of the Chinese Society of Toxicology, Executive Director of the First Council of the Shanghai Society of Toxicology, Member of the Professional Committee of Drug Toxicology and Safety Evaluation of the Chinese Society of Toxicology, member of the American Society for Quality Assurance (SQA), US Registered GLP QA Professional (RQAP-GLP).

Xing Guozhen

ZSHK Laboratories Limited CTO
General Manager of Anling Biomedical (Suzhou) Co., Ltd.

See more

Dr. Xing Guozhen is currently the CTO of ZSHK Laboratories Limited. and the executive deputy general manager of Anling Biomedical (Shenzhen) Co., Ltd. He got his PhD for pharmacology from Chinese Academy of Sciences. He is senior engineer and the Master mentor in the Nanjing University of Traditional Chinese Medicine. He is also is the member of the second CPPCC Committee in Pingshan District, Shenzhen. He used to be the head of drug research and development of CDSER in Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and was the deputy general manager of Jiangsu Dingtai Pharmaceutical Research Co., Ltd. As well as the deputy director of the GLP test facility. Guozhen Xing had won the second prize of the National Science and Technology Progress Award (5th in 2013). He also was the winner of the fifth "333 high-level talent" plan of Jiangsu Province, and the winner of Wuhan East Lake 3551 talent plan (innovation), and won the Chinese Pharmaceutical Association Science and Technology Award (3 times) and other honorary titles.
He had published more than 30 SCI research papers in domestic and foreign academic journals such as Arch Toxicol, Mutat Res, International Journal of Molecular Science, Genes and Environment and had obtained 10 authorized patents. He had given more than 10 speeches in national conferences; as the project leader, He had completed more than 100 projects in research and development, and helped clients to successfully develop new drugs into the clinic, and carried out multi-country declarations; as the person in charge, he has undertaken scientific research projects such as the National New Drug Creation Science and Technology Major Project and the (Youth) Natural Science Foundation;
Other current social positions: Reviewer of "Natural Product Research and Development", member of the Safety Pharmacology Professional Committee of the Chinese Pharmacological Society, Youth Member of the Drug Toxicology and Safety Evaluation Professional Committee of the Chinese Toxicological Society, and the board member of the Jiangsu Toxicological Society etc.

Ying MU, PhD, DABT

ZSHK Laboratories Limited CSO

See more

Ying Mu, PhD, DABT joined Zhongke Shanghai-Hong Kong (ZSHK) International Biotechnology Co., Ltd. as a Chief Scientific Officer in 2022. He is a board-certified toxicologist with nine years of experience at FDA in the Center for Devices and Radiological Health (CDRH) and the Center for Drug Evaluation and Research (CDER). Dr. Mu was formerly Toxicologist and Principal Investigator in the Division of Biology, Chemistry, and Materials Science, Office of Science and Engineering Laboratories (CDRH), and Pharmacology and Toxicology Reviewer in the Division of Special Pathogen and Transplant Products, Office of New Drugs (CDER). Prior to his FDA career, he was a Research Assistant Professor in the School of Pharmacy at the University of Pittsburgh, where he worked on nuclear receptors, mediated gene regulation, mechanism of action in efficacy and safety, and new molecule entity identification and development.

Dr. Mu is a highly-respected toxicologist, acting as an expert consultant for several US and Chinese companies, with more than 25 years of life science research experience and a broad array of knowledge, including biomarkers, toxicology, pharmacology, PK/PD, immunology, cell therapy, stem cell, tissue engineering, biomaterials, biocompatibility, medicine, animal modeling, molecular-cell biology, mechanism of action, drug-device combination, pre-market risk assessments, post-market safety evaluation, the filing and the regulation. He has published 28 peer-reviewed articles, and holds a PhD in Medicine from Gunma University, Japan. He is fluent in Japanese, English and Chinese.
  • Total 1 Page/4 Records
Copyright © AnLing Biomed (Suzhou) Co., Ltd. All Rights Reserved Source:Boooming ICP:粤ICP备2022021434号-2 CNZZ